

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1680108> since 2018-10-31T17:03:40Z

Published version:

DOI:10.3851/IMP3140

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1 **Plasma Non-detectable HIV RNA and Cerebrospinal Fluid Viral Load and Neopterin in HIV-**
2 **positive HAART-treated patients**

3
4 MOTTA Ilaria¹, ALLICE Tiziano², ROMITO Alessandra³, FERRARA Micol¹, ECCLESIA Sara¹,
5 IMPERIALE Daniele⁴, GHISSETTI Valeria², DI PERRI Giovanni¹, BONORA Stefano¹ and
6 CALCAGNO Andrea¹

7
8 *¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino;* *²Laboratory of*
9 *Microbiology and Molecular Biology, Ospedale Amedeo di Savoia, ASL TO2, Torino;* *³Laboratory*
10 *of Immunology, Ospedale Maria Vittoria, ASL TO2, Torino;* *⁴Unit of neurology, Ospedale Maria*
11 *Vittoria, ASL TO2, Torino;*

12
13 **Running Head:** CSF undetectable HIV RNA

14
15 **Type of article:** Short communication

16
17 **Figures:** 2

18
19 **Tables:** 1

20
21 **Words count:** 1249

22
23 **Abstract words count:** 191

24
25 **Corresponding Author:**

26 Ilaria Motta,
27 Department of Infectious Diseases, University of Torino
28 c/o Ospedale Amedeo di Savoia,
29 C.so Svizzera 164
30 10159, Torino, Italy
31 +390114393884, fax +390114393818
32 ilaria.motta@unito.it
33

34
35 **Abbreviations:**

36 TND Target not detected, CSF cerebrospinal fluid, LLV low level viremia
37
38
39
40

41

42 Abstract**43 Background**

44 Cerebrospinal fluid (CSF) HIV RNA is commonly used as a marker of compartmental antiviral
45 activity in HIV-positive patients. Undetectable CSF HIV RNA levels have been associated with low
46 CSF neopterin levels and better neurocognitive performances. Aim of this study was to analyse the
47 prevalence and predictors of non-detectable CSF HIV RNA using a commercial assay.

48 Methods

49 In adult HIV-positive HAART-treated patients with confirmed plasma HIV RNA <50 copies/mL,
50 CSF HIV RNA (with Roche Amplicor Assay) and neopterin were measured.

51 Results

52 112 adult patients were included. Plasma and CSF HIV-RNA was non-detectable (TND) in 29
53 (25.9%) and 36 (32.1%) patients, respectively. CSF TND was observed more frequently in patients
54 with plasma TND ($p=0.005$, $OR=3.87$). CSF neopterin levels were associated with age ($\rho=0.333$,
55 $p=0.002$) and current ($\rho=-0.272$, $p=0.015$) and nadir ($\rho=-0.240$, $p=0.038$) CD4+ T
56 lymphocytes; the lowest CSF neopterin concentration was observed in patients with CSF TND
57 versus other viral load strata (0.62 mg/dl vs. 0.78 mg/dL, $p=0.048$).

58 Conclusions

59 Efficaciously treated HIV-positive patients with detectable plasma HIV RNA might imperfectly
60 control CSF viral replication. Prospective studies addressing the management and neurocognitive
61 consequences of CSF low level viremia are warranted.

62

63 **Key words:** low level viral load, CSF, central nervous system, neuroefficacy, neopterin.

64

65 **Background**

66 After penetration in central nervous system HIV-infected cells may express neurotoxins leading to
67 permeable blood brain barrier and to neuronal injury. (1,2) Cerebrospinal fluid (CSF) HIV RNA is
68 the most commonly used marker of compartmental viral replication in HIV-positive patients
69 although its relationship with brain tissue viral load is not uniform. (3,4)

70 Neopterin is a well-established early marker of intrathecal immune response, and particularly of
71 macrophage activation. The CSF neopterin levels are elevated in most HIV-1-infected individuals
72 and decrease significantly after initiation of antiretroviral therapy achieving CSF concentrations
73 observed in HIV-negative subjects. (5) Two exceptions have been reported: low CSF neopterin
74 levels in patients treated during primary HIV infection (6) and in those with undetectable CSF HIV
75 RNA by ultra-sensitive methods. (7-10)

76 Following such evidence, maintaining an undetectable CSF HIV RNA would be one of the long-
77 term objectives of antiretroviral therapy. Unfortunately proven strategies to reach such target are
78 lacking.

79 **Objectives**

80 Aim of this study was to analyse the prevalence and predictors of non-detectable CSF HIV RNA.

81 **Study design**

82 The study was conducted at the Unit of Infectious Diseases, Department of Medical Sciences,
83 University of Torino, Italy between January 2013 and February 2015. Ethics Committee approval
84 was obtained (Comitato Etico Interaziendale, Ospedale San Luigi Gonzaga, Orbassano Torino) and
85 all patients provided a written informed consent.

86 Adult HIV-positive HAART-treated patients enrolled in a prospective ongoing cohort with
87 confirmed plasma HIV RNA <50 copies/mL (at least two determinations, the latter in the previous

88 30 days) undergoing lumbar punctures for clinical reasons were included. Exclusion criteria
89 included the presence of central nervous system infectious, inflammatory or neoplastic lesions.

90 Routine cerebrospinal fluid examinations (including HIV RNA, resistance associated mutations and
91 neopterin) were performed. Neopterin (normal value <1.5 ng/ml) was analysed with an enzyme-
92 linked immunosorbent assay. HIV-1 RNA quantification was performed with the Roche Amplicor
93 assay (version 2.0; Hoffman-La Roche, Basel, Switzerland) with a lower limit of quantification of
94 20 copies/mL. CNS concentration penetration effectiveness score (CPE) was derived from
95 Hammond et al. (11)

96 Data are expressed as medians (interquartile range). Non-parametric tests were used for all analysis
97 using SPSS software for Macintosh (version 22.0, IBM Corp.).

98

99 **Results**

100 One hundred-twelve patients were included; subjects' characteristics are shown in **Table 1**.
101 Previous syphilis was recorded in 18 (16.1%) subjects. Plasma HIV-RNA was TND, <20 cp/ml and
102 20-50 cp/ml in 29 (25.9%), 65 (58%) and 18 (16.1%) patients. Antiretroviral regimens were mostly
103 based on the association of 2 NRTIs (95 patients, 84.8%) plus either a PI (81 patients, 72.3%)
104 followed by a NNRTI (16 patients, 14.3%) or a integrase inhibitor (14 patients, 12.5%). Median
105 CPE was 7 (IQR 6-8).

106 CSF HIV RNA was TND, <20, 20-50 and >50 cp/ml in 36 (32.1%), 35 (31.3%), 11 (9.8%) and 30
107 (26.8%) patients, respectively; in those subjects with CSF HIV RNA >50 copies/mL its median
108 value was 122 copies/mL (73-185). Median CSF neopterin was 0.6 (0.48-1.07) ng/ml; it was >1.5
109 ng/ml in 9 patients (8%).

110


	n or median	% or IQR
		111
Gender: male	74	66.1%
Ethnicity: Caucasian	81	72.3%
Age: years	47.9	40.9-56.2
HBsAg positive	12	10.7%
HCV Ab positive	30	26.8%
Liver cirrhosis	15	13.4%
Nadir CD4 cell count: n/uL	86	11-215
Current CD4 cell count: n/uL	387	194-601
Estimated duration of HIV infection: years	11.9	2.8-18.9
Reason for lumbar puncture		120
Longitudinal cohort	46	41.1%
Neurocognitive disorders	24	21.4%
White matter abnormalities	13	11.6%
Differential diagnosis	13	11.6%
Long-term follow up of opportunistic infections	11	9.8%
Persistent headache	7	6.2%

126 **Table 1. Characteristics of included patients.**

127 **HBsAg**, hepatitis B surface antigen. **HCV Ab**, hepatitis C virus antibody. **IQR**, interquartile range.

128


129 CSF TND was more common in patients with plasma TND [16 out of 29 patients (55.2%) vs. 20
 130 out of 83 patients (24.1%), $p=0.005$, $OR=3.87$] (**Fig.1**). No other variable was significantly
 131 associated with non-detectable HIV RNA in the CSF.



132

133 **Figure 1. Prevalence of cerebrospinal fluid viral load strata according to plasma viral load**
 134 **levels. TND, target not detectable.**

135 CSF neopterin levels correlated with CSF HIV RNA ($\rho=-0.22$, $p=0.048$) with lower values in
 136 patients with TND as compared to those in other CSF viral load strata [0.62 ng/mL (0.41-0.923) vs.
 137 others 0.78 ng/mL (0.54-1.21), $p=0.048$] (**Fig. 2**) but not in patients with plasma TND (0.73 vs.
 138 0.63 ng/mL, $p=0.512$). Furthermore CSF neopterin levels showed a weak inverse correlation with
 139 current ($\rho= -0.272$, $p=0.015$) and nadir ($\rho=-0.240$, $p=0.038$) CD4+ T lymphocytes and a direct
 140 correlation with age ($\rho=0.333$, $p=0.002$).



141

142 **Fig 2. Cerebrospinal fluid neopterin concentrations according to CSF viral load strata.**

143 Horizontal lines represent median values; boxes represent interquartile ranges while whiskers are
 144 10-90 percentiles. TND, target not detectable.

145

146 **Conclusions**

147 The main results of this analysis are that the non-detectable CSF HIV RNA was observed more
 148 frequently in patients with plasma non-detectable plasma HIV RNA (suggesting this as a possible
 149 screening marker for optimal viral control) and that it was associated with the lowest CSF neopterin
 150 concentrations (suggesting that it may be a good target for CNS-oriented antiretroviral therapy).

151 Our aim was to analyse the prevalence and predictors of non-detectable CSF HIV viral load by
 152 using the Roche Amplicor Assay: this test is able to discriminate non-detectable RNA (associated
 153 with better virological control and less risk of future treatment failures) to non-quantifiable but
 154 detectable RNA (less than 20 copies/mL). Sensitive CSF HIV RNA analyses have been performed
 155 so far using single copy assay thus requiring a large quantity of cerebrospinal fluid collected (above

156 7 mL for this determination) and expensive laboratory work. (5,8) Using a commercial assay might
157 provide useful and clinically applicable information.

158 Some limitations should be acknowledged such as the cross-sectional design and the heterogeneous
159 reasons for performing lumbar punctures.

160 Several determinants of CSF viral control have been identified so far including plasma HIV RNA
161 <50 copies/mL, depression, duration of HAART, HAART adherence and nadir CD4 cell count.
162 (11-14) The role of different drugs is debated: higher CPE scores have been associated in most
163 studies with lower CSF HIV RNA (13,15,16) even if treatment intensification was reported to have
164 no effect in controlling residual CSF replication. (17) The association of CPE with better
165 neurocognitive outcomes is even more controversial. (18,19) In patients with less drug pressure and
166 specifically on protease inhibitors monotherapy a low nadir CD4 cell count was associated with
167 CSF escape and neurological symptoms. (20) Furthermore individual CSF concentrations, rather
168 than estimated penetration, might inform on the compartmental efficacy of antiretroviral regimens
169 (12).

170 We were here able to identify optimal plasma control as the only predictor of CSF undetectable
171 HIV RNA. In several studies LLV was associated with virological failure, with viral reservoirs size
172 and, recently, with CSF escape. (21-27)

173 We also confirmed what Yilmaz and Dahl (5,8) observed in previous studies: only patients with the
174 lowest residual CSF HIV RNA showed the lowest levels of immune activation. Impact of residual
175 HIV RNA has been linked to higher levels of immune activation and pro-inflammatory cytokines in
176 periphery and we suggest this observation could be assumed as possible explanation of our result.

177 Early treatment for all HIV-positive patients might be beneficial in preventing advanced immune
178 suppression, even if an overall neurocognitive advantage (or disadvantage) was not found for
179 immediate ART initiation in asymptomatic treatment-naive individuals with high CD4 counts.

180 (27,28). Data have been published showing neurocognitive improvement in HAART patients
181 treated regardless of CD4 cell count and those treated during primary HIV infection where
182 neopterin level normalized after early initiation of HAART. (6, 30, 31)

183 Occasional CSF HIV-RNA may be clinically benign and represent low fluctuations in release of
184 virus into the CSF rather than lack of treatment efficacy. (32,33) Dahl et al. found that patients who
185 had detectable viral replication at one point did not have elevated CSF neopterin levels at other time
186 points. (8) This observation suggests that such patients may not have “chronic” immune activation
187 in the CSF but rather the release of very low levels of HIV-RNA that may lead to macrophage
188 activation and neopterin production even during suppressive therapy.

189 Is HAART not enough to control viral induced immune response? Reducing HIV replication in the
190 brain may not have effects on other processes involved in neuronal injury, including ongoing
191 immune activation. Several data suggested that maraviroc might have additional positive effect in
192 the central nervous system possibly by interfering with immune activation processes. (34,35)

193 Prospective studies addressing the management and neurocognitive consequences of very low level
194 CSF HIV RNA and immune-activation are warranted. Possible adjunctive therapies, beside
195 efficacious antiretroviral treatments, are needed.

196

197 **Acknowledgements**

198 GDP and SB has received grants, travel grants, and consultancy fees from Abbvie, Boehringer-
199 Ingelheim, BMS, MSD, Gilead, Janssen-Cilag and Viiv. AC has received grants from Gilead and
200 Bristol-Myers Squibb (BMS), travel grants and speaker’s honoraria from Abbvie, BMS, Merck
201 Sharp & Dohme (MSD), Gilead, Janssen-Cilag and Viiv. Other authors declare no potential conflict
202 of interest.

203 **Authors’ contribution**

204 AC, SB, DI, VG designed the study. IM, MF and SE enrolled the patients and followed the study
205 procedures. AR, TA performed the plasma and CSF analysis. AC, IM and SB analysed the data and
206 wrote the draft of the manuscript. AC, SB, VG, DI and GDP reviewed the paper. All authors made
207 substantial contributions to this manuscript and agreed on its preparation in tis present form.
208

209 **References**

- 210 1. Rao VR, Eugenin EA, Prasad VR. Evaluating the Role of Viral Proteins in HIV-Mediated
211 Neurotoxicity Using Primary Human Neuronal Cultures. *Methods Mol Biol* 2016; **1354**:367-
212 76.
- 213 2. Calcagno A, Atzori C, Romito A, Vai D, Audagnotto S, Stella ML et al. Blood brain barrier
214 impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-
215 positive patients. *J Neurovirol* 2016; **22**(1):88-92.
- 216 3. Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR et al. Cerebrospinal fluid
217 human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively
218 impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral
219 Research Center Group. *Ann Neurol* 1997; **42**:679–88.
- 220 4. Wiley CA, Achim CL, Christopherson C, Kidane Y, Kwok S, Masliah E et al. HIV mediates
221 a productive infection of the brain. *AIDS* 1999; **13**(15):2055-9.
- 222 5. Yilmaz A, Yiannoutsos CT, Fuchs D, Price RW, Crozier K, Hagberg L et al. Cerebrospinal
223 fluid neopterin decay characteristics after initiation of antiretroviral therapy. *J*
224 *Neuroinflammation* 2013; **10**:10:62.
- 225 6. Peluso MJ, Valcour V, Ananworanich J, Sithinamsuwan P, Chalermchai T, Fletcher JL et al.
226 Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate
227 Antiretroviral Therapy in Acute HIV Infection. *J Infect Dis* 2015; **212**(11):1759-67.
- 228 7. Perez-Valero I, Heaton R, Franklin D, Letendre S, Deutsch R, Gelman B, et al. HIV-
229 replication control rates needed to prevent neurocognitive performance (NP) decline.
230 [Abstract] 21st CROI Conference on Retroviruses and Opportunistic Infections 2014, Boston
231 March 3-6, 2014.
- 232 8. Dahl V, Peterson J, Fuchs D, Gisslen M, Palmer S, Price RW. Low levels of HIV-1 RNA
233 detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated

- 234 with local immune activation. *AIDS* 2014; **28**(15):2251-8.
- 235 9. Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Persistent intrathecal
236 immune activation in HIV-1-infected individuals on antiretroviral therapy. *J Acquir Immune*
237 *Defic Syndr* 2008; **47**(2):168-73.
- 238 10. Edén A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B et al. HIV-1 viral
239 escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. *J Infect Dis*
240 2010; **202**(12):1819-25.
- 241 11. Hammond ER, Crum RM, Treisman GJ, Mehta SH, Marra CM, Clifford DB et al. The
242 cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons
243 with HIV. *Am J Epidemiol* 2014; **180**(3):297-307.
- 244 12. Calcagno A, Simiele M, Alberione MC, Bracchi M, Marinaro L, Ecclesia S et al.
245 Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are
246 associated with compartmental viral control. *Clin Infect Dis* 2015; **60**(2):311-7.
- 247 13. Rawson T1, Muir D, Mackie NE, Garvey LJ, Everitt A, Winston A. Factors associated with
248 cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture
249 examination in a clinical setting. *J Infect* 2012; **65**(3):239-45.
- 250 14. Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A et al. Cerebrospinal fluid HIV
251 escape associated with progressive neurologic dysfunction in patients on antiretroviral
252 therapy with well controlled plasma viral load. *AIDS* 2012; **26**(14):1765-74.
- 253 15. Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA et al. Higher CNS
254 penetration-effectiveness of long-term combination antiretroviral therapy is associated with
255 better HIV-1 viral suppression in cerebrospinal fluid. *J Acquir Immune Defic Syndr* 2013;
256 **62**(1):28-35.
- 257 16. Vassallo M, Durant J, Biscay V, Lebrun-Frenay C, Dunais B, Laffon M et al. Can high
258 central nervous system penetrating antiretroviral regimens protect against the onset of HIV-

- 259 associated neurocognitive disorders? *AIDS* 2014; **28**(4):493-501.
- 260 17. Yilmaz A, Verhofstede C, D'Avolio A, Watson V, Hagberg L, Fuchs D et al. Treatment
261 intensification has no effect on the HIV-1 central nervous system infection in patients on
262 suppressive antiretroviral therapy. *J Acquir Immune Defic Syndr* 2010; **55**(5):590-6.
- 263 18. Calcagno A, Di Perri G, Bonora S. Pharmacokinetics and pharmacodynamics of
264 antiretrovirals in the central nervous system. *Clin Pharmacokinet* 2014; **53**(10):891-906.
- 265 19. Carvalhal A, Gill MJ, Letendre SL, Rachlis A, Bekele T, Raboud J et al. Central nervous
266 system penetration effectiveness of antiretroviral drugs and neuropsychological impairment
267 in the Ontario HIV Treatment Network Cohort Study. *J Neurovirol* 2015.
- 268 20. Antinori A, Arribas J, Fehr J, Girard PM, Horban A, Hill A et al. The PROTEA trial:
269 darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA
270 below 50 copies/mL. *J Int AIDS Soc* 2014; **17**(4 Suppl 3):19525.
- 271 21. Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A et al. Plasma HIV-1 RNA
272 detection below 50 copies/ml and risk of virologic rebound in patients receiving highly
273 active antiretroviral therapy. *Clin Infect Dis* 2012; **54**(5):724-32.
- 274 22. Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, Gregis G et al. Ultrasensitive
275 assessment of residual low-level HIV viremia in HAART-treated patients and risk of
276 virological failure. *J Acquir Immune Defic Syndr* 2012; **60**(5):473-82.
- 277 23. Calcagno A, Motta I, Ghisetti V, Lo Re S, Alice T, Marinaro L et al. HIV-1 very low level
278 viremia is associated with virological failure in highly active antiretroviral treatment-treated
279 patients. *AIDS Res Hum Retroviruses* 2015; **31**(10):999-1008.
- 280 24. Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C et al. Relationship
281 between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected
282 individuals receiving effective antiretroviral therapy. *J Infect Dis* 2011; **204**(1):135-138.
- 283 25. Pascual-Pareja JF, Martinez-Prats L, Luczkowiak J, Fiorante S, Rubio R, Pulido F et al.
284 Detection of HIV-1 at between 20 and 49 copies per milliliter by the Cobas TaqMan HIV-1

- 285 v2.0 assay is associated with higher pretherapy viral load and less time on antiretroviral
286 therapy. *J Clin Microbiol* 2010; **48**(5):1911–1912.
- 287 26. Bonora S, Nicastrì E, Calcagno A, Gonzalez de Requena D, D'Ettorre G, Sarmati L et al.
288 Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with
289 persistently undetectable plasma HIV-RNA: A cross-sectional evaluation. *J Med Virol* 2009;
290 **81**(3):400–405.
- 291 27. Nightingale S, Geretti AM, Beloukas A, et al. Discordant CSF/plasma HIV-1 RNA in
292 patients with unexplained low-level viraemia. *J Neurovirol*. 2016 Epub ahead of print.
- 293 28. The INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early
294 Asymptomatic HIV Infection. *N Engl J Med* 2015; 373:795-807.
- 295 29. Wright E, Grund B, Robertson K. No difference between the effects of immediate versus
296 deferred ART on neuropsychological test performance in HIV-positive adults with CD4+
297 cell counts above 500 cells/ μ l: the Strategic Timing of Anti Retroviral Treatment (START)
298 Neurology Substudy. [Abstract] 15th European AIDS Conference, October 21-24, 2015,
299 Barcelona.
- 300 30. Kore I, Ananworanich J, Valcour V, Fletcher JL, Chalermchai T, Paul R et al.
301 Neuropsychological Impairment in Acute HIV and the Effect of Immediate Antiretroviral
302 Therapy. *J Acquir Immune Defic Syndr* 2015; **70**(4):393-9.
- 303 31. Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B et al. Central nervous system
304 immune activation characterizes primary human immunodeficiency virus 1 infection even in
305 participants with minimal cerebrospinal fluid viral burden. *J Infect Dis* 2011; **204**(5):753-60.
- 306 32. Edén A, Hagberg L, Svennerholm B, Price RW, Gisslén M. Longitudinal follow up of
307 detectable HIV-1 RNA in cerebrospinal fluid in subjects on suppressive antiretroviral
308 therapy. [Abstract] 19th CROI Conference on Retroviruses and Opportunistic Infections
309 2012, Seattle March 5-8, 2012.
- 310 33. Pérez-Valero I, González-Baeza A, Estébanez M, Montes-Ramírez ML, Bayón C, Pulido F

- 311 et al. Neurocognitive impairment in patients treated with protease inhibitor monotherapy or
312 triple drug antiretroviral therapy. PLoSOne. 2013; **8**(7).
- 313 34. Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, Mayer H et al. Effects of
314 maraviroc and efavirenz on markers of immune activation and inflammation and
315 associations with CD4 cell rises in HIV-infected patients. PLoS One 2010; **5**(10).
- 316 35. Gates TM, Cysique LA, Chaganti J, Siefried KJ, Brew BJ. Maraviroc-enhanced cART
317 improves cognition in virally-suppressed HAND: a pilot study. [Abstract] 22nd CROI
318 Conference on Retroviruses and Opportunistic Infections 2015, Seattle February 23-26,
319 2015.
- 320